Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rebus Holdings Inc (CE) | RBSH | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.000001 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.000001 | 0.000001 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.000001 - 0.02255 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.000001 | USD |
Rebus Holdings Inc (CE) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 32.13M | - | 0 | -1.02M | -0.03 | 0.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rebus (CE) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/21/2023 | 16:19 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/14/2023 | 15:36 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RBSH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.000001 | 0.0001 | 0.000001 | 0.000001 | 3,769 | 0.00 | 0.00% |
| 1 Month | 0.000001 | 0.0001 | 0.000001 | 0.000001 | 3,769 | 0.00 | 0.00% |
| 3 Months | 0.0001 | 0.0001 | 0.000001 | 0.0000995 | 269,679 | -0.0001 | -99.00% |
| 6 Months | 0.0059 | 0.0088 | 0.000001 | 0.0025693 | 247,719 | -0.0059 | -99.98% |
| 1 Year | 0.0102 | 0.02255 | 0.000001 | 0.0080411 | 139,362 | -0.0102 | -99.99% |
| 3 Years | 0.0999 | 0.12 | 0.000001 | 0.0226551 | 277,389 | -0.0999 | -100.00% |
| 5 Years | 0.0999 | 0.12 | 0.000001 | 0.0226551 | 277,389 | -0.0999 | -100.00% |
Rebus (CE) Description
| Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types. |
